scholarly journals Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment

2020 ◽  
Vol 35 (2) ◽  
pp. 443-455 ◽  
Author(s):  
Oksana Sulaieva ◽  
Olena Chernenko ◽  
Oleksiy Selesnov ◽  
Oleksandr Nechay ◽  
Oleksandr Maievskyi ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Hashimoto Thyroiditis ◽  
Papillary Thyroid ◽  
Immune Microenvironment ◽  
Tumor Immune Microenvironment ◽  
The Impact

Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management

2021 ◽  
Author(s):  
Anello Marcello Poma ◽  
David Viola ◽  
Elisabetta Macerola ◽  
Agnese Proietti ◽  
Eleonora Molinaro ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Low Risk ◽  
World Health ◽  
American Thyroid Association ◽  
Papillary Thyroid ◽  
Cell Percentage ◽  
Tall Cell ◽  
Definition Of ◽  
The Impact

Abstract Purpose Recent diagnostic criteria updates of the tall cell variant of papillary thyroid carcinoma (TCPTC) by the World Health Organization (WHO) have determined the inclusion of tumours with 30-49% of tall cells. However, the impact of tall cell percentage on papillary thyroid carcinoma (PTC) patients’ prognosis is still debated. We aimed to evaluate whether tall cell percentage affects patients’ outcome in the absence of aggressive features. Methods Rates of aggressive features, recurrence-free survival (RFS) and distant RFS (DRFS) (5-year median follow-up) were compared among tumours with less than 30%, 30-49% and at least 50% of tall cells. We also evaluated the impact of the new tall cell cut-off on patient management. Results Overall, 3092 tumours (15.7% of all PTC) were collected: 792 PTC had less than 30%, 503 had 30-49%, and 1797 had 50% or more tall cell areas. With the new definition of WHO, the number of TCPTC increased by 28%. There were no differences in recurrence rates according to tall cell percentage. The coexistence of BRAF and TERT promoter mutations predicted a worse RFS. Considering the new definition of TCPTC, the level of risk according to the American Thyroid Association increased from low to intermediate in 4.2% of cases. However, the recurrence rate within this subgroup was comparable to low-risk. Conclusions TCPTC and PTC with tall cell areas can be considered as a unique group with similar recurrence risk. However, whenever aggressive features are absent, tumors have a low risk of recurrence independently of tall cell percentage.

scholarly journals The Clinical Relevance of Psammoma Body and Hashimoto Thyroiditis in Papillary Thyroid Carcinoma

Medicine ◽  
2015 ◽  
Vol 94 (44) ◽  
pp. e1881 ◽  
Author(s):  
Ye-Feng Cai ◽  
Qing-Xuan Wang ◽  
Chun-Jue Ni ◽  
Gui-Long Guo ◽  
Quan Li ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Clinical Relevance ◽  
Hashimoto Thyroiditis ◽  
Psammoma Body ◽  
Papillary Thyroid

scholarly journals Association between Thyroiditis and Multifocality in Papillary Thyroid Carcinoma

2020 ◽  
Author(s):  
Rogério Aparecido Dedivitis ◽  
Leandro Luongo de Matos ◽  
Felipe Guilherme Silva Souza ◽  
Jose Luis Bogado Ortiz
Keyword(s):  
Retrospective Study ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Total Thyroidectomy ◽  
Direct Relationship ◽  
Statistical Significance ◽  
Hashimoto Thyroiditis ◽  
Papillary Thyroid ◽  
Multifocal Lesions ◽  
The Relationship

Abstract Introduction Hashimoto thyroiditis (HT) shares many characteristics with papillary thyroid carcinoma (PTC), and some studies show that, when associated, PTC is diagnosed mostly with smaller lesions and multifocal pattern. Objective To evaluate the relationship between HT and PTC. Methods A retrospective study of 155 patients who underwent total thyroidectomy from 2009 to 2015. Demographical, clinical and ultrasonographical data, as well as anatomopathological findings were evaluated. Results There were signs of thyroidits in 35 patients, and 114 patients had a unifocal disease. There was no statistical significance between the variables studied and thyroiditis. However, when compared with the occurrence of unifocal or multifocal lesions, there was statistical significance regarding age (p = 0.038) and mass (p = 0.031). There was no direct relationship between thyroiditis and multifocality (p = 0.325) nor between thyroiditis and cervical extension of the disease (p = 0.300 e p = 0.434). Conclusion There was no relationship between thyroiditis and multifocality in cases of PTC.

Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?

2014 ◽  
Vol 20 (3) ◽  
pp. 463-473 ◽  
Author(s):  
Hee Yong Kwak ◽  
Byung Joo Chae ◽  
Yong Hwa Eom ◽  
Young Ran Hong ◽  
Jae Beom Seo ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Hashimoto Thyroiditis ◽  
Papillary Thyroid

scholarly journals A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma

2017 ◽  
Vol 6 (3) ◽  
pp. R8-R17 ◽  
Author(s):  
Huy Gia Vuong ◽  
Uyen N P Duong ◽  
Ahmed M A Altibi ◽  
Hanh T T Ngo ◽  
Thong Quang Pham ◽  
...  
Keyword(s):  
Molecular Markers ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Random Effect ◽  
Random Effect Model ◽  
Disease Free Survival ◽  
Papillary Thyroid ◽  
Promoter Mutation ◽  
Meta Analyses ◽  
The Impact

The prognostic role of molecular markers in papillary thyroid carcinoma (PTC) is a matter of ongoing debate. The aim of our study is to investigate the impact of RAS, BRAF, TERT promoter mutations and RET/PTC rearrangements on the prognosis of PTC patients. We performed a search in four electronic databases: PubMed, Scopus, Web of Science and Virtual Health Library (VHL). Data of hazard ratio (HR) and its 95% confidence interval (CI) for disease-specific survival (DSS) and disease-free survival (DFS) were directly obtained from original papers or indirectly estimated from Kaplan–Meier curve (KMC). Pooled HRs were calculated using random-effect model weighted by inverse variance method. Publication bias was assessed by using Egger’s regression test and visual inspection of funnel plots. From 2630 studies, we finally included 35 studies with 17,732 patients for meta-analyses. TERT promoter mutation was significantly associated with unfavorable DSS (HR = 7.64; 95% CI = 4.00–14.61) and DFS (HR = 2.98; 95% CI = 2.27–3.92). BRAF mutations significantly increased the risk for recurrence (HR = 1.63; 95% CI = 1.27–2.10) but not for cancer mortality (HR = 1.41; 95% CI = 0.90–2.23). In subgroup analyses, BRAF mutation only showed its prognostic value in short-/medium-term follow-up. Data regarding RAS mutations and RET/PTC fusions were insufficient for meta-analyses. TERT promoter mutation can be used as an independent and reliable marker for risk stratification and predicting patient’s outcomes. The use of BRAF mutation to assess patient prognosis should be carefully considered.

Sign in / Sign up

Export Citation Format

Share Document